Banque Cantonale Vaudoise Makes New $2.07 Million Investment in Kenvue Inc. (NYSE:KVUE)

Key Points

• Banque Cantonale Vaudoise acquired 86,281 shares of Kenvue Inc., valued at approximately $2,069,000, during the first quarter, highlighting increasing institutional interest in the company.
• Kenvue has announced a quarterly dividend of $0.2075 per share, representing a yield of 3.82%, up from the previous $0.21 dividend.
• Recent analyst ratings show a consensus of "Hold" for Kenvue, with an average price target lowered to $24.79 amidst decreasing expectations from firms like UBS and Citigroup.

Banque Cantonale Vaudoise purchased a new stake in Kenvue Inc. (NYSE:KVUE - Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 86,281 shares of the company's stock, valued at approximately $2,069,000.

A number of other hedge funds also recently bought and sold shares of KVUE. Pittenger & Anderson Inc. purchased a new position in Kenvue during the first quarter valued at approximately $30,000. TruNorth Capital Management LLC acquired a new stake in shares of Kenvue during the 1st quarter valued at $36,000. Bank Julius Baer & Co. Ltd Zurich grew its holdings in shares of Kenvue by 120.6% during the 1st quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,699 shares of the company's stock valued at $41,000 after acquiring an additional 929 shares in the last quarter. Clarity Asset Management Inc. acquired a new position in shares of Kenvue in the fourth quarter worth $45,000. Finally, Continuum Advisory LLC increased its stake in shares of Kenvue by 2,071.1% in the first quarter. Continuum Advisory LLC now owns 1,954 shares of the company's stock worth $47,000 after acquiring an additional 1,864 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Price Performance

Shares of Kenvue stock traded up $0.55 during midday trading on Monday, reaching $22.14. The company had a trading volume of 9,247,731 shares, compared to its average volume of 17,229,514. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.63. The stock has a fifty day simple moving average of $21.82 and a 200 day simple moving average of $22.40. Kenvue Inc. has a 1-year low of $18.10 and a 1-year high of $25.17. The company has a market capitalization of $42.48 billion, a price-to-earnings ratio of 40.25, a price-to-earnings-growth ratio of 3.62 and a beta of 0.83.

Kenvue (NYSE:KVUE - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, topping analysts' consensus estimates of $0.23 by $0.01. The company had revenue of $3.74 billion during the quarter, compared to the consensus estimate of $3.69 billion. Kenvue had a return on equity of 20.87% and a net margin of 6.90%. The firm's quarterly revenue was down 3.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.28 earnings per share. As a group, equities research analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, August 27th. Stockholders of record on Wednesday, August 13th will be given a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a dividend yield of 3.7%. The ex-dividend date is Wednesday, August 13th. This is an increase from Kenvue's previous quarterly dividend of $0.21. Kenvue's dividend payout ratio is presently 149.09%.

Analyst Ratings Changes

A number of research analysts have commented on KVUE shares. Redburn Atlantic started coverage on Kenvue in a research note on Thursday, April 10th. They issued a "neutral" rating and a $23.50 target price on the stock. Citigroup dropped their price objective on Kenvue from $24.50 to $22.00 and set a "neutral" rating on the stock in a report on Tuesday, July 15th. UBS Group reduced their target price on shares of Kenvue from $25.00 to $23.00 and set a "neutral" rating for the company in a research note on Thursday, July 17th. Bank of America reduced their price objective on Kenvue from $27.00 to $25.00 and set a "buy" rating for the company in a research report on Tuesday, July 15th. Finally, Barclays cut their target price on Kenvue from $23.00 to $22.00 and set an "equal weight" rating for the company in a research note on Tuesday, July 15th. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $24.79.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.